Precision Healthcare & Regenerative Medicine

Incontinence is a significant unmet clinical need. Cell therapy offers a promising solution to restoring the function of muscles that provide continence. Early clinical studies have reported mixed results, with some studies showing no improvement in muscle function. This is likely due to the cells being delivered in a sub-optimal condition due to their manipulation outside the body and delivery as a suspension, an unnatural state for a muscle cell. To address this, we are developing highly porous biodegradable implantable microcarriers that are used as a substrate to grow patients' own muscle progenitor cells (myoblasts) in vitro, before delivering them, still anchored to microcarriers, into the defective muscle. The microcarriers are designed to slowly degrade as the myoblasts integrate with the host muscle, forming new functional tissue that will restore continence. 

Notably, we have received funding from Horizon 2020, the EU's research and innovation funding programme, for the AMELIE project, one of UCL’s most ambitious translational tissue engineering studies to date. This involves testing the implantable microcarriers in a clinical trial involving patients from two clinical sites in the UK.

People involved:

• Professor Richard Day
• Dr Chara Simitzi
• Professor Charles Knowles (Queen Mary University London; Cleveland Clinic London)
• Dr William English (Academic Surgical Registrar - Royal London Hospital; PhD Fellow UCL & Cleveland Clinic London)
• UCLH/UCL Joint Research Office, UCL Comprehensive Clinical Trials Unit, UCL Translational Research Office
• AMELIE consortium

In addition to the AMELIE project, the Day Lab has multiple projects where we are bringing patients, scientists, and clinicians together to enable innovative collaboration and research. Many of these projects are at an early stage and need funds to enable them to move forward.

As a supporter, your generosity funds innovative, promising research initiatives that might otherwise go unfunded.

You can make a donation towards our pioneering research here. Your gift makes a difference in supporting our mission to cure incontinence in adults and children.

If you would like further information, please contact Prof Richard Day (r.m.day@ucl.ac.uk)

Fistulas are abnormal connections between two epithelialized surfaces e.g., blood vessels, bladder, intestines, or other hollow organs. The goal of fistula surgery is to close the fistula whilst trying to avoid damage to the surrounding tissue. A range of materials have been used to fill fistulas in an attempt to promote healing but all of these have failed because the material becomes dislodged and falls out or results in an infection. We have developed highly porous microspheres to overcome this problem. When packed into a fistula the microspheres provide a 'scaffold' that cells can easily grow between and into. As the microspheres slowly dissolve, they are replaced by new tissue.

Funding from the Wellcome Trust has enabled us to conduct a pioneering first-in-man clinical safety study, which has shown they are safe to use and improve fistula healing. Moreover, the microspheres are UCL's first biomaterial for regenerative medicine granted approval for clinical use in a regulated device trial by the Medicines and Healthcare Products Regulatory Agency (MHRA).

People involved:

• Professor Richard Day
• Mr James Crosbie (University College London Hospital)
• Mr Willian English (University College London)
• Dr David Brealey (University College London Hospital)
• Professor Charles Knowles (Queen Mary University London)
• UCL Translational Research Office

Extracellular vesicles (EV) are nano- to micron-sized vesicles with lipid bilayers ranging from 30 to 1,000 nm in diameter that are secreted by most cell types. EVs are being utilised in a wide range of biomedical applications, including “liquid biopsies” for biomarker discovery, vaccine development, tissue regeneration, drug delivery, and gene therapy. We are interested in how the way cells are grown can influence the quantity and quality of EVs produced, as described in our review article. This multidisciplinary project is investigating whether bio-manufacturing of EVs will be improved through the identification of parent cell substrates in the form of microcarriers that are inspired by physicochemical conditions known to enhance EV production.

People involved:

• Professor Richard Day
• Professor Costanza Emanueli (Imperial College London)
• Professor Sean Davidson
• Juzheng Zhang (PhD student)

This multidisciplinary project funded by the British Heart Foundation is developing a platform technology involving iPSC-derived cardiac organoids to investigate inherited diseases, such as hypertrophic cardiomyopathy, and safety testing of potentially cardiotoxic drugs. Organoid models of human tissue provide unique advantages for modelling human disease compared with the use of animal models and will become increasingly important for testing new therapies. 

People involved:

• Professor Richard Day
• Dr Petros Syrris (UCL Institute of Cardiovascular Sciences)
• Imogen Heenan (BHF-funded PhD student)

This multifaceted programme of research has received funding from the British Heart Foundation and involves investigating novel biomaterial-based approaches for therapeutic angiogenesis. The unique surface topography of biodegradable and biocompatible TIPS microparticles is being utilised for its angiogenic potential, both alone and in combination with cells including mesenchymal stromal cells and pericytes. If successful, the novel approach could be used as a curative treatment for life-threatening diseases such as coronary heart disease and peripheral arterial disease.

People involved:

• Professor Richard Day
• Dr Charikleia Simitzi
• Dr Caroline Pellet-Many (Royal Veterinary College)
• Professor Paolo Madeddu (Section of Regenerative Medicine, University of Bristol)

Ischaemic heart disease is a global health issue. Myocardial ischaemia is of particular significance, resulting in the irreversible and extensive loss of cardiomyocytes. Cell therapy provides a potential therapy for cardiac muscle regeneration and various teams around the world are attempting to utilise cell-based strategies for this purpose. However, loss of cell viability and retention of cells following delivery into the myocardium poses a significant challenge that risks reducing potency of the therapy.

This BHF-funded project is a collaboration with Professors Sanjay Sinha's lab at the University of Cambridge and builds on preliminary studies that show TIPS microparticles provide a potential substrate for attachment and growth of cardiomyocytes derived from induced pluripotent stem cells (iPSC). The aim of the project is to investigate the use of TIPS microparticles for targeted delivery of iPSC-derived cardiomyocytes into cardiac tissue to improve cell viability and engraftment for myocardial regeneration.

People involved:

• Professor Richard Day
• Annalisa Bettini
• Dr Daniel Stuckey, UCL Division of Medicine
• Dr Maria Colzani (Anne McLaren Laboratory, Cambridge Stem Cell Institute, University of Cambridge)
• Dr Sanjay Sinha (Anne McLaren Laboratory, Cambridge Stem Cell Institute, University of Cambridge)

We have an extensive research programme investigating the use of TIPS microspheres for cell expansion and targeted, minimally invasive delivery for cell therapy purposes. We have developed regulator-approved bioprocessing techniques for producing implantable cell-microsphere combinations compatible for clinical translation as investigational products in muscle regeneration and have other clinical applications in the pipeline. 

We are interested in the use of biomaterials for the control and targeted delivery of the cell secretome. We are particularly interested in how this effect can be utilised for the delivery of angiogenic growth factors to treat cardiovascular disease.

We have developed a novel cell seeding device for large hollow organs that consists of a Halbach array of magnets. The magnets attract cells loaded with magnetic nanoparticles towards the surface of the hollow scaffold and hold them in place until they have adhered to the substrate surface. This process can deliver cells more uniformly and efficiently to the surface of scaffolds compared with traditional cell seeding methods that involve rolling or rotating the scaffold.

Building on this concept, and with funding from the UK Engineering & Physical Sciences Research Council and EPSRC Centre for Innovative Manufacturing in Regenerative Medicine, we have invented a magnetic cell seeding device compatible with hollow organ bioreactors.

Inflammation and the associated immune response are central to the host's defence against infection. They are also implicated in diverse states ranging from atherosclerosis to cancer, and an increasingly common and important target for therapeutic modulation. Inter-individual variance in response to noxious challenges (e.g. pathogens and trauma) and frequently employed drugs, likely contributes to disease states such as sepsis and immune dysfunction following major surgery. Despite this, we are yet to fully characterize and integrate patients' immunophenotypes into their care, or monitor immune competence in the clinical setting.

Using experimental models in healthy volunteers and samples taken from patients undergoing surgery, we are exploring the molecular and biochemical pathways that underlie immune variance and dysfunction. We are additionally seeking to develop new techniques, methods and tools to quantify leukocyte functionality. We hope this will lead to personalized medicine strategies that improve outcomes in the critically ill and perioperative populations amongst others.

People involved:

• Dr James Fullerton
• Joao Oliveira
• Professor Richard Day

Antibiotic resistance poses a catastrophic risk to human health. Novel approaches that provide alternatives to antibiotics for combating infection are urgently sought.  Re-evaluation of existing small molecules with well-established disinfectant properties, especially in terms of optimizing their mode of delivery, could offer an accelerated pathway to the clinic for a range of new therapeutic products. Reactive oxygen species, such as hydrogen peroxide, are effective microbicidal agents but, as with any medicinal product, are also capable of causing significant non-specific tissue damage if delivered in an uncontrolled manner.

This industry-funded project aims to validate the novel antimicrobial strategy centred on the targeted and controlled release of reactive oxygen species and other oxidizing agents via TIPS microparticle technology. It will investigate whether the strategy is effective in pre-clinical models that mimic typical clinical scenarios of infection.

People involved:

• Professor Richard Day
• AGA Nanotech Ltd

Livestock farming drives global warming and consumes vast water and land resources. Our research is exploring cultivated meat as a sustainable alternative. A major challenge is finding suitable, edible, and eco-friendly materials for cell growth, as current options are limited, expensive, and polluting. We are investigating the use of bacterial cellulose, a natural dietary fibre that can serve as a growth scaffold. Traditionally, its production requires costly liquid feed, but we have shown biomass waste from the brewing industry can be used as a low-cost, sustainable source. Repurposing this waste enables the creation of abundant, affordable, and food-safe materials. This solution not only advances cultivated meat toward mainstream adoption but also promotes a circular economy by reducing waste and lowering emissions. Ultimately, our approach provides a greener pathway for cultivated meat, reinforcing its potential to support global net-zero targets.

Our research in this area has received attention from national and international media organisations.

Read about our impact

People involved:

• Professor Richard Day
• Christian Harrison (PhD student)

Glaucoma and trachoma are leading causes of blindness worldwide, with a combined >200M people affected and close to 10M at immediate risk of permanent sight loss. For both diseases, surgical treatment success is directly dependent on the avoidance of postoperative scarring. However, there is no treatment to prevent scarring in trachoma and the current drugs used to prevent scarring following filtration surgery for glaucoma can have serious blinding side effects. With funding from the Wellcome Trust and UKRI Medical Research Council, we have designed an innovative product consisting of biodegradable microspheres loaded with doxycycline, a common drug, for local delivery at the time of surgery to achieve safe, targeted and sustained anti-scarring action. These have shown remarkable anti-scarring efficacy in laboratory tests. We now aim to develop this treatment towards clinical trials, with a potential benefit to millions worldwide.

People involved:

• Professor Richard Day
• Professor Maryse Bailly (UCL Institute of Opthalmology)
• Professor Sir Peng Khaw (Moorfields Eye Hospital)
• Professor Matthew Burton (London School of Hygiene & Tropical Medicine)
• Elif Gokoglan (PhD student)

Prostate cancer is a leading cause of mortality in men. About 9,000 men undergo radical prostatectomy every year in the UK with 10-20% requiring adjuvant or salvage (radiation) therapy or systemic chemotherapy. Failure can occur because cancer cells are shed during surgery, incomplete excision or metastatic disease. Adjuvant or salvage therapy confers additional harm through collateral damage to the bladder, urethra and rectum whilst systemic therapy confers toxicity related to chemotherapy effects.
With funding from Cancer Research UK and UCL Business, we have developed a novel approach that combines surgery with precise delivery of anti-cancer cytotoxic therapy immediately after prostate removal. This will be achieved through a unique combination of degradable microparticles loaded with a chemotherapy drug. The microparticles will elute the drug in a controlled manner to target cancer cells potentially shed during surgery, whilst avoiding collateral tissue damage associated with systemic delivery.
This project is investigating combining docetaxel, a clinically approved anti-cancer drug, with an implantable scaffold consisting of TIPS microparticles validated for clinical use. This approach is novel and potentially transformative.

People involved:

• Professor Richard Day
• Professor Hashim Ahmed (Imperial College London)

Intrapericardial drug delivery is an uncommon route where drugs are administered directly into the pericardium, a bi-layered sac surrounding the heart that possesses several physiological functions. The space enclosed by the pericardium (known as the intrapericardial space) contains about 20-40 mL of fluid. Owing to its proximity to the myocardium and slow clearance, this space could be employed for the delivery of cardioprotective agents to treat myocardial infarction. The project will combine advances in polymer engineering and nanotechnology to engineer a formulation system that can deliver cardioprotective drugs to the infarcted myocardium via the intrapericardial space.

With funding from EPSRC, we have utilised established processing technology to produce polymer-based nanocarriers that contain cardioprotective agents for intrapericardial administration. Release of the cargo will be dictated by degradation of the polymer and/or diffusion, which can be moderately refined depending on the molecular mass of the polymer, particle size, shape and porosity. 

In addition to ischaemic heart disease, it is anticipated that the new technology will be applicable to other diseases where the controlled release of drugs will be beneficial.

People involved:

• Mr Kenneth Ho
• Professor Richard Day
• Professor Duncan Craig (UCL School of Pharmacy)

This project investigates a novel approach for adoptive T cell therapy that involves using biodegradable, biocompatible TIPS microparticles to stimulate a targeted, tumour-specific effector response and expansion of T cells in the immunosuppressive tumour microenvironment. If successful, the proposed technology will provide a step-change for adoptive cell therapy by improving tumour immunity and reducing the risk of toxicities that arise from on-target/off-tumour cross reactivity. The project involves the functionalisation of TIPS particles with azide groups necessary for Strain-Promoted Azide-Alkyne Cycloaddition (SPAAC) that will enable the conjugation of antibody fragments to the surface of solid PLGA particles.

People involved:

• Professor Richard Day
• Dr Vijay Chudasama (UCL Department of Chemistry)
• Mr João Carlos Nogueira (UCL Department of Chemistry)

This BBSRC-funded PhD project involves designing materials to control immune cell behaviour. In particular, the project explores integrating engineering principles with immunology to create biomaterials that can quantitatively control T-cell activation and expansion. Towards this goal, the project is investigating how immune cells respond to biophysical and biochemical cues over different time and length scales. It is hoped insights gained from these studies can be used to improve adoptive T-cell therapy both in terms of cost-effectiveness and processing.

People involved:

• Professor Richard Day
• Prof Marc-Olivier Coppens (UCL Chemical Engineering)

We are investigating the use of magnetic field gradients to manipulate the position and behaviour of cells in the body. This involves either loading cells with nanoparticles of iron that are susceptible to an externally applied oscillating magnetic field or introducing magnetic material into the extracellular environment. Both approaches can be used to deliver different amounts of strain to cells that can be used to provide a biological stimulus.

We have built a series of magnetic actuator devices that we are using in conjunction with mathematical modelling to explore how the delivery of a magnetic field gradient influences the phenotype of cells.
The research offers tremendous opportunities for a variety of healthcare applications, ranging from the targeted delivery of stem cells for tissue engineering to the conditioning of damaged or degenerated muscle groups.

People involved:

• Professor Richard Day
• Professor Quentin Pankhurst